No abstract available
Plain language summary
This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.
MeSH terms
-
Antibodies, Monoclonal*
-
Hematologic Neoplasms* / complications
-
Hematologic Neoplasms* / drug therapy
-
Humans
-
Patients
Substances
-
tixagevimab
-
cilgavimab
-
Antibodies, Monoclonal